Lisa M Pickering
Overview
Explore the profile of Lisa M Pickering including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Halabi S, Yang Q, Carmack A, Zhang S, Foo W, Eisen T, et al.
Kidney Cancer J
. 2021 Nov;
19(3):64-72.
PMID: 34765076
Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC), particularly papillary renal cell carcinoma, in order to inform on initial treatment selection and identify potentially novel targets...
2.
Nicholson S, Tovey H, Elliott T, Burnett S, Cruickshank C, Bahl A, et al.
Br J Cancer
. 2021 Oct;
126(1):34-41.
PMID: 34671131
Background: We investigated the first-line activity of vinflunine in patients with penis cancer. Cisplatin-based combinations are commonly used, but survival is not prolonged; many patients are unfit for such treatment...
3.
Armstrong A, Nixon A, Carmack A, Yang Q, Eisen T, Stadler W, et al.
Clin Cancer Res
. 2021 Jun;
27(12):3503.
PMID: 34117029
No abstract available.
4.
Armstrong A, Nixon A, Carmack A, Yang Q, Eisen T, Stadler W, et al.
Clin Cancer Res
. 2021 Feb;
27(12):3317-3328.
PMID: 33593885
Purpose: Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC) to inform treatment selection but also to identify novel therapeutic targets. We thus sought to profile circulating...
5.
Khan Y, Slattery T, Pickering L
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33322163
Therapeutic options for treating advanced renal cell cancer (RCC) are rapidly evolving. Vascular endothelial growth factor (VEGF)-directed therapy, predominantly VEGF receptor (VEGFr) tyrosine kinase inhibitors (TKIs) had been the most...
6.
Eisen T, Frangou E, Oza B, Ritchie A, Smith B, Kaplan R, et al.
J Clin Oncol
. 2020 Oct;
38(34):4064-4075.
PMID: 33052759
Purpose: SORCE is an international, randomized, double-blind, three-arm trial of sorafenib after surgical excision of primary renal cell carcinoma (RCC) found to be at intermediate or high risk of recurrence....
7.
Patel R, English L, Liu W, Tree A, Ayres B, Watkin N, et al.
Int Urol Nephrol
. 2020 Jul;
52(12):2301-2306.
PMID: 32705478
Purpose: Red cell distribution width (RDW) measures red cells' size variability. Metastatic penile cancer displays poor chemotherapy response. As no validated prognostic predictor exists, we investigated whether RDW correlates independently...
8.
Hussain S, Ansari J, Huddart R, Power D, Lyons J, Wylie J, et al.
Int J Oncol
. 2017 Jan;
50(3):768-772.
PMID: 28098864
There is no standard of care in the UK or Ireland for second-line chemotherapy for patients with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients who have...
9.
Armstrong A, Halabi S, Eisen T, Broderick S, Stadler W, Jones R, et al.
Lancet Oncol
. 2016 Jan;
17(3):378-388.
PMID: 26794930
Background: Non-clear cell renal cell carcinomas are histologically and genetically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We aimed to compare the mTOR inhibitor...
10.
Pickering L, Mahgoub M, Mukherji D
Curr Opin Urol
. 2015 Jun;
25(5):390-4.
PMID: 26075569
Purpose Of Review: Metastatic renal cell carcinoma (mRCC) is a diagnosis with wide variation in outcome; prognostic categories of favourable, intermediate and poor risk based on clinical criteria are widely...